trial · primary record
RLY-8161
Advanced NRAS-Mutant Melanoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 180 |
| Primary completion | 2031-06-30 |
| Primary endpoint | Part 1: Maximum Tolerated Dose (MTD) and/or RP2D of RLY-8161 |
| Registry ID | NCT07584226 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:51.693Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07584226
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.